States / West Virginia / HB 4626
HB 4626 Vetoed
Relating to the establishment of a grant program to fund the United States Food and Drug Administration’s drug development trials with ibogaine
Introduced
In Committee
Floor
Crossed Over
Passed
Enacted
Apr 2, 2026 · House
Vetoed by Governor 4/1/2026
Mar 31, 2026 · House
To Governor 3/31/2026
Mar 14, 2026 · Senate
To Governor 3/31/2026 - Senate Journal
Mar 14, 2026 · Senate
Vetoed by Governor 4/1/2026 - Senate Journal
Mar 14, 2026 · House
Vetoed by Governor 4/1/2026 - House Journal
Mar 13, 2026 · House
House received Senate message
Mar 12, 2026 · Senate
On 3rd reading
Mar 12, 2026 · Senate
Read 3rd time
Mar 12, 2026 · Senate
Passed Senate (Roll No. 487)
Mar 12, 2026 · Senate
Communicated to House
Mar 12, 2026 · Senate
Completed legislative action
Mar 11, 2026 · Senate
On 2nd reading
Mar 11, 2026 · Senate
Read 2nd time
Mar 10, 2026 · Senate
On 1st reading
Mar 10, 2026 · Senate
Read 1st time
Mar 9, 2026 · Senate
Reported do pass
Feb 18, 2026 · Senate
Reported do pass, but first to Finance
Feb 18, 2026 · Senate
To Finance
Jan 30, 2026 · Senate
Introduced in Senate
Jan 30, 2026 · Senate
To Health and Human Resources then Finance
Jan 30, 2026 · Senate
To Health and Human Resources
Jan 29, 2026 · House
On 3rd reading, Special Calendar
Jan 29, 2026 · House
Read 3rd time
Jan 29, 2026 · House
Passed House (Roll No. 32)
Jan 29, 2026 · House
Communicated to Senate
Jan 28, 2026 · House
On 2nd reading, Special Calendar
Jan 28, 2026 · House
Read 2nd time
Jan 27, 2026 · House
On 1st reading, Special Calendar
Jan 27, 2026 · House
Read 1st time
Jan 26, 2026 · House
On 1st reading, Special Calendar
Jan 23, 2026 · House
Do pass
Jan 22, 2026 · House
Markup Discussion
Jan 21, 2026 · House
Filed for introduction
Jan 21, 2026 · House
To Health and Human Resources
Jan 21, 2026 · House
Introduced in House
Jan 21, 2026 · House
To House Health and Human Resources